Toppublicaties

Prostaatcarcinoom

Geselecteerd door: Prostaatcarcinoom
Duiding door dr. André Bergman

Combinatie enzalutamide en docetaxel vertraagt progressie prostaatcarcinoom
  • oktober 2022

Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study

  • Prof Axel S Merseburger, Gerhardt Attard, Lennart Åström, et al.
  • oktober 2022

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial

  • James P Buteau, Andrew J Martin, PhD Prof Louise Emmett, et al.
  • augustus 2022

Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)

  • Johnathan K. Joffe, Fay H. Cafferty , Laura Murphy, et al.
  • mei 2022

The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.

  • Pollack A, Karrison TG, Balogh AG, et al.
  • mei 2022

Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial.

  • Hussain SA, Lester JF, Jackson R, et al.
Duiding door dr. André Bergman

Androgeendeprivatie, docetaxel en abirateron effectief tegen prostaatkanker
  • april 2022

Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.

  • Fizazi K, Foulon S, Carles J, et al.
Duiding door dr. André Bergman

Androgeendeprivatie, docetaxel en abirateron effectief tegen prostaatkanker
  • maart 2022

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

  • Matthew R. Smith, M.D., Ph.D., Maha Hussain, M.D., Fred Saad, M.D., et al.
  • januari 2022

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

  • Prof Arlene O Siefker-Radtke, MD Prof Andrea Necchi, MD Se Hoon Park, MD, et al.
  • januari 2022

Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial

  • Thomas Powles, Kobe C. Yuen, Silke Gillessen, Edward E. Kadel III
Duiding door Dr. André Bergman

Lutetium-177-PSMA-617 zorgt voor overlevingswinst bij prostaatkanker
  • november 2021

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

  • Oliver Sartor, M.D., Johann de Bono, M.B., Ch.B., Ph.D., Kim N. Chi, M.D., et al.
Duiding door Dr. André Bergman

Apalutamide plus abirateron leidt niet tot overlevingswinst
  • november 2021

Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study

  • Saad F, Efstathiou E, Attard G, et al.
  • september 2021

Radiation and Androgen Deprivation Therapy With or Without Docetaxel in the Management of Nonmetastatic Unfavorable-Risk Prostate Cancer: A Prospective Randomized Trial

  • D’Amico AV, Xie W, McMahon E, et al.
Gedownload van https://medischeoncologie.nl/ op 22-03-2023 om 13:00. Copyright (C) 2023 BPM Medica.

Deel deze pagina